全文获取类型
| 收费全文 | 20238篇 |
| 免费 | 1505篇 |
| 国内免费 | 34篇 |
专业分类
| 耳鼻咽喉 | 133篇 |
| 儿科学 | 756篇 |
| 妇产科学 | 558篇 |
| 基础医学 | 2446篇 |
| 口腔科学 | 272篇 |
| 临床医学 | 3143篇 |
| 内科学 | 3599篇 |
| 皮肤病学 | 208篇 |
| 神经病学 | 1803篇 |
| 特种医学 | 424篇 |
| 外国民族医学 | 1篇 |
| 外科学 | 1592篇 |
| 综合类 | 667篇 |
| 一般理论 | 39篇 |
| 预防医学 | 2959篇 |
| 眼科学 | 417篇 |
| 药学 | 1119篇 |
| 中国医学 | 9篇 |
| 肿瘤学 | 1632篇 |
出版年
| 2023年 | 92篇 |
| 2022年 | 120篇 |
| 2021年 | 356篇 |
| 2020年 | 240篇 |
| 2019年 | 353篇 |
| 2018年 | 396篇 |
| 2017年 | 293篇 |
| 2016年 | 385篇 |
| 2015年 | 432篇 |
| 2014年 | 563篇 |
| 2013年 | 937篇 |
| 2012年 | 1353篇 |
| 2011年 | 1411篇 |
| 2010年 | 687篇 |
| 2009年 | 634篇 |
| 2008年 | 1212篇 |
| 2007年 | 1332篇 |
| 2006年 | 1317篇 |
| 2005年 | 1306篇 |
| 2004年 | 1309篇 |
| 2003年 | 1241篇 |
| 2002年 | 1181篇 |
| 2001年 | 246篇 |
| 2000年 | 222篇 |
| 1999年 | 235篇 |
| 1998年 | 250篇 |
| 1997年 | 233篇 |
| 1996年 | 220篇 |
| 1995年 | 208篇 |
| 1994年 | 179篇 |
| 1993年 | 149篇 |
| 1992年 | 169篇 |
| 1991年 | 154篇 |
| 1990年 | 171篇 |
| 1989年 | 144篇 |
| 1988年 | 178篇 |
| 1987年 | 112篇 |
| 1986年 | 134篇 |
| 1985年 | 118篇 |
| 1984年 | 129篇 |
| 1983年 | 131篇 |
| 1982年 | 97篇 |
| 1981年 | 120篇 |
| 1980年 | 94篇 |
| 1979年 | 101篇 |
| 1978年 | 83篇 |
| 1977年 | 81篇 |
| 1976年 | 83篇 |
| 1974年 | 91篇 |
| 1973年 | 65篇 |
排序方式： 共有10000条查询结果，搜索用时 46 毫秒
1.
2.
Christian Holm Hansen Shelley Lees Saidi Kapiga Janet Seeley Tony Barnett 《Global public health》2020,15(3):402-413
ABSTRACTMeasuring hope reliably and accurately remains an important research objective, not least in less prosperous settings where ‘holding on to hope’ may be critically important in the struggle against adverse life conditions. The State Hope Scale was designed for use in the US. Despite reported application in diverse cultures and using translations the scale has not been extensively validated outside US populations. This study contributes to a larger project exploring the measurement of hope and provides a critique of Snyder’s scale as used in a Tanzanian female population of 1021 urban microfinance participants. We evaluate the scale’s validity through assessment of the empirical distribution of scores, item response profiles, internal consistency and discriminatory ability. Participants mostly scored very high and many reached very near the maximum attainable score. Hardly any endorsed the negative half of the response scale. Several problems are discussed including poor discrimination and strong evidence of acquiescence response bias. We also found little association of the scale scores with hypothesised correlates of hope. Future improvements on the measurement of hope are recommended, especially in studies outside the narrow Western context in which the scale was devised. 相似文献
3.
ABSTRACTThis work collates data from the analysis of complex mixtures analysed in STRmix during routine no-suspect volume crime work. It interrogates the upload rate for these types of mixtures and which component of the profile has been able to be interpreted for upload. The number of profiles giving multiple uploads and the amount of replicate PCR analysis has been collated. 相似文献
4.
5.
6.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献7.
8.
Christopher J. Destache David J. Guervil Keith S. Kaye 《International journal of antimicrobial agents》2019,53(5):644-649
Background
The clinical experience of ceftaroline fosamil (CPT-F) therapy for Gram-positive infective endocarditis is reported from CAPTURE, a retrospective study conducted in the USA.Methods
Data, including patient demographics, medical history, risk factors, microbiological aetiology and clinical outcomes, were collected by review of patient charts between September 2013 and February 2015.Results
Patients (n=55) with Gram-positive endocarditis were treated with CPT-F. The most common risk factors were intravascular devices (43.6%), diabetes mellitus (40.0%) and injection drug use (38.2%). The most commonly isolated pathogens were meticillin-resistant Staphylococcus aureus (MRSA; 80%), meticillin-susceptible S. aureus (MSSA; 7.3%) and coagulase-negative staphylococci (7.3%). CPT-F was given as first-line therapy in 7.3% of patients and as second-line or later therapy in 92.7% of patients, and as monotherapy in 41.8% of patients and as concurrent therapy in 58.2% of patients. Clinical success was observed in 82.6% (19/23) of patients treated with CPT-F as monotherapy. In patients treated with CPT-F as first-line therapy or second-line or later therapy, 75.0% (3/4) and 70.6% (36/51) achieved success, respectively. Clinical success was observed in 77.3% (34/44) of patients with MRSA and 25% (1/4) of patients with MSSA. Two patients discontinued treatment with CPT-F due to an adverse event.Conclusions
CPT-F treatment was associated with a high rate of clinical success in patients with Gram-positive infective endocarditis, including those with risk factors and infections caused by MRSA. A high rate of clinical success was observed in patients treated with CPT-F used as first- line therapy or second-line or later therapy, or as monotherapy or in combination with other antibiotics. 相似文献9.
10.